Penn Medicine Provider
Medical Oncology
Mark Diamond, MD, PhD
5.0
(256)
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital
Make an appointmentCall 800-789-7366

About me

  • Clinical Assistant Professor of Medicine (Hematology-Oncology)

Education and training

  • Medical School: Washington University in St. Louis
  • Residency: NewYork-Presbyterian/Weill Cornell Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
5.0

256 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
professional and knowledgeable
April 2025
5.0
5.0
dr diamond is very polite and courteous as well as informative
April 2025
5.0
5.0
the best team
April 2025
5.0
5.0
i always feel better and informed after my visit

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Diamond is a Penn Medicine physician.

Qualifications and experience

My research

Diamond, MS, Lin, JH, Vonderheide, RH Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming , Cancer Immunol Res , 9(8): 2021,877-890

Vishruth K Reddy, Varsha Jain, Robert J Wilson Ii, Lee P Hartner, Mark Diamond, Ronnie A Sebro, Kristy L Weber, Robert G Maki, Jacob E Shabason Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database , Sarcoma , 13: 2021,1:9712070.

Morrison, AH, Diamond, MS, Hay, CA, Byrne, KT, Vonderheide, RH. Sufficiency of CD40 activate and immune checkpoint blockade for T cell priming and tumor immunity. , Proc Natl Acad Sci U S A , 117(14): 2020,8022-8031

Rebecca A Evans, Mark S Diamond, Andrew J Rech, Timothy Chao, Max W Richardson, Jeffrey H Lin, David L Bajor, Katelyn T Byrne, Ben Z Stanger, James L Riley, Nune Markosyan, Rafael Winograd, Robert H Vonderheide Lack of immunoediting in murine pancreatic cancer reversed with neoantigen , JCI Insight , 1(14): 2016,e88328.

Diamond, M., Gangadhar, T., Schuchter, L.M Immunotherapy for Melanoma. Abeloff’s Clinical Oncology Updates. , Elsevier : 2015

Mark S Diamond, Michelle Kinder, Hirokazu Matsushita, Mona Mashayekhi, Gavin P Dunn, Jessica M Archambault, Hsiaoju Lee, Cora D Arthur, J Michael White, Ulrich Kalinke, Kenneth M Murphy, Robert D Schreiber Type I interferon is selectively required by dendritic cells for immune rejection of tumors , J Exp Med , 208(10): 2011,1989-2003

Kai Hildner, Brian T Edelson, Whitney E Purtha, Mark Diamond, Hirokazu Matsushita, Masako Kohyama, Boris Calderon, Barbara U Schraml, Emil R Unanue, Michael S Diamond, Robert D Schreiber, Theresa L Murphy, Kenneth M Murphy Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity , Science , 322(5904): 2008,1097-100

Kathleen C F Sheehan, Koon Siew Lai, Gavin P Dunn, Allen T Bruce, Mark S Diamond, Jennifer D Heutel, Corazon Dungo-Arthur, Javier A Carrero, J Michael White, Paul J Hertzog, Robert D Schreiber Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection , J Interferon Cytokine Res , 26(11): 2006,804-19

Gavin P Dunn, Allen T Bruce, Kathleen C F Sheehan, Vijay Shankaran, Ravindra Uppaluri, Jack D Bui, Mark S Diamond, Catherine M Koebel, Cora Arthur, J Michael White, Robert D Schreiber A critical function for type I interferons in cancer immunoediting , Nat Immunol , 6(7): 2005,722-9